Avalo TherapeuticsAVTX
13F holders, Q2 2024 (June 30)21holders +3
7new positions
4sold out
$12.47avg. 13F price*
At the end of Q2 2024, 21 institutions reported holding Avalo Therapeutics Inc. (AVTX) in their 13F filings, up 3 from Q1 2024. 7 opened new positions and 4 sold out. The largest holders were Logos Global Management LP ($6.7M), Sio Capital Management, LLC ($891K) and Ikarian Capital, LLC ($682K).
- Company
- Avalo Therapeutics Inc.
- CUSIP
- 05338F306
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $7.4M |
| Exits | 4 | $221K |
All 13F filers, Q1 2024 → Q2 2024: 699,709 shares bought and 16,114 shares sold, net +683,595 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 21 holders
| Logos Global Management LP | 0.77% | New | 539,079 | $6.7M |
| Sio Capital Management, LLC | 0.34% | Add +604.0% | 71,458 | $891K |
| Ikarian Capital, LLC | 0.21% | Add +17.3% | 54,730 | $682K |
| Affinity Asset Advisors, LLC | 0.10% | Add +350.0% | 45,000 | $561K |
| Commodore Capital LP | 0.03% | New | 40,000 | $499K |
| Vanguard Group Inc. | 0.00% | New | 10,368 | $129K |
| Bank of America Corp. | 0.00% | New | 5,601 | $70K |
| UBS Group AG | 0.00% | Reduce -53.5% | 3,583 | $45K |
| Royal Bank of Canada | 0.00% | Add +83.2% | 590 | $7K |
| BlackRock Inc. | 0.00% | Reduce -84.5% | 329 | $4K |
| Banque Cantonale Vaudoise | 0.00% | No change | 338 | $4K |
| Morgan Stanley | 0.00% | Reduce -74.4% | 10 | $124 |
| BNP Paribas Financial Markets | 0.00% | No change | 4 | $50 |
| JPMorgan Chase & Co. | 0.00% | No change | 2 | $25 |
| FMR LLC | 0.00% | New | 2 | $25 |
| Group One Trading LLC | 0.00% | No change | 2 | $25 |
| Osaic Holdings, Inc. | 0.00% | No change | 2 | $24 |
| Wells Fargo & Company | 0.00% | Reduce -87.5% | 1 | $12 |
| Parallel Advisors, LLC | 0.00% | No change | 1 | $12 |
| Key Financial Inc | 0.00% | New | 1 | $12 |
| Activest Wealth Management | 0.00% | New | 1 | $12 |
"% of holder's portfolio" is AVTX's weight in each manager's 13F, not the share of Avalo Therapeutics Inc. the manager owns.